BGNE241220C175000
- 0.00
- 0.000.00%
BeiGene Newsroom
BeiGene Price Target Announced at $300.00/Share by Morgan Stanley
BeiGene Analyst Ratings
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
Research Reports Prospecting丨China Merchants Securities: First gives Beigene a "strong buy" rating, bullish on the rapid increase in sales of products such as Zejula in the short to medium term.
BeiGene (688235): Deeply understanding the field of disease and entering the global competitive stage
Major Bank Rating | bocom intl: Raises beigene target price to 159 HKD, catalysts are about to be densely launched.
Research reports highlight | Soochow Securities: Beigene's growth certainty is relatively high, maintaining a "buy" rating.
BeiGe-U (688235): Overseas sales lead in rapid volume hematoma industry
bocom intl: raised beigene (06160) target price to 159 Hong Kong dollars. Q3 product sales and operation continue to improve.
[Brokerage Focus] Bocom Intl raises the target price of Beigene (06160) and points out that product sales and operation continue to improve in Q3 2024.
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
BeiGene's Strong Financial Performance and Growth Potential Justifies Buy Rating
Research reports Focus丨Tianfeng: Beigene Q3 adjusted operating profit reached $65.6 million, maintaining a "buy" rating
[Brokerage Focus] Guoyuan International cuts Beigene (06160) target price to HK$153, pointing to 3Q24 performance slightly below expectations.
BEIGENE LTD(6160.HK):3Q24 REVENUE MILESTONE OF US$1BN+ WITH ROBUST PIPELINE PROGRESS DESPITE SIGNS OF MARKET MODERATION
BeiGene (688235): Continuous profit core under NON-GAAP caliber, excellent clinical data in the research pipeline
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Analyst Ratings